Start the program by clicking on the Start Program icon at the bottom of this page.
|
| Program Title |
 |
|
MGMT Methylation and Its Role in GBM
Release Date: May-13-09
Credit Expiration Date: May-31-10
|
|
|
 |
| Program Developer/Facilitator |
 |
|
Medical Communications Media, Inc. |
|
|
|
| Target Audience |
|
|
| This educational activity is designed to meet the needs of neurosurgeons, neuro-oncologists, radiation oncologists, medical oncologists, and other healthcare providers interested in the treatment of primary gliomas. |
|
|
|
| Credit Hours |
|
|
|
|
|
| Medium |
|
|
|
|
|
| Program Description |
|
|
| In the ongoing effort to develop more effective treatments for malignant gliomas, translational research has exposed many of the genetic and molecular secrets of these tumors. One of the most important findings is that in glioblastomas, the DNA repair enzyme methylguanine methyltransferase (MGMT) can be up- or down-regulated based on whether or not the tumor’s MGMT promoter gene is methylated. Those whose tumors have methylated promoter genes demonstrate improved survival rates because MGMT is less able to repair the DNA damage from therapeutic cytotoxic agents. This brief educational activity focuses on the role that MGMT methylation may play in glioblastoma disease progression and the therapeutic approaches that may best correlate to MGMT promoter methylation status. |
|
|
|
| Learning Objectives |
|
|
|
|
|
| Faculty |
|
|
Arnab Chakravarti, MD
Chair & Professor, Department of Radiation Oncology
Ohio State University Medical School
Co-Director, Brain Tumor Program
Arthur G. James Comprehensive Cancer Center and
Richard L. Solove Research Institute
Columbus, OH
|
|
|
|
| Disclosures |
|
|
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Dr. Chakravarti discloses that he serves on the speakers’ bureau of Schering-Plough and is a consultant for Genentech.
|
|
|
|
| Commercial Support Statements |
|
|
This activity is supported by an educational grant from Schering-Plough. |
|
|
|
|
|
| Credit Statements |
|
|
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians. |
|
|
AKH Inc. designates this educational activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
|
|
|
|
|
| Instructions |
|
|
|
|
|
| Certificate Fee |
|
|
|
|
|
| Disclaimer |
|
|
| © 2009. All rights reserved. None of the contents of this publication may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication are those of the faculty members and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Schering-Plough. Any medications, diagnostic procedures, or treatments discussed by the faculty members should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities. |
|
|
| |
